Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04635189
PHASE2

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

Sponsor: University of Rochester

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.

Official title: A Phase II Study of Steroid Sparing Treatment With Daratumumab and Lenalidomide in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

28

Start Date

2021-07-27

Completion Date

2026-07-31

Last Updated

2025-08-08

Healthy Volunteers

No

Interventions

DRUG

Daratumumab

Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks

DRUG

Lenalidomide

Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle

DRUG

Dexamethasone

Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab

Locations (1)

University of Rochester Medical Center

Rochester, New York, United States